Home › NDC Lookup › Ingredients › Hydroquinone › 62032-0100-36
NU-DERM BLENDER Skin Lightener and Blending HYDROQUINONE 40 mg/g Cream, 57 g — NDC 62032-0100-36 package photo
Label image from the product's FDA listing (DailyMed) — may show a different pack size or an older label revision.

NU-DERM BLENDER Skin Lightener and Blending HYDROQUINONE 40 mg/g Cream, 57 g — NDC 62032-100-36 (Billing 62032-0100-36)

by Obagi Cosmeceuticals LLC · 57 g in 1 BOTTLE, PLASTIC

This is a package of 57 g of NU-DERM BLENDER Skin Lightener and Blending HYDROQUINONE 40 mg/g Cream from Obagi Cosmeceuticals LLC, marketed since Jan 1988 and currently FDA-listed.

NDC 62032-0100-36
🏷️ FDA NDC (as labeled) 62032-100-36 billing pads the product segment with a zero
This package
Contains57 g Pack sizes2 compare ↓
Product page 62032-0100-10 Also comes in: 28 g 62032-100-10
Rx only On market Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Oct 1, 2026 · this listing last changed Oct 1, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

NDC database record

One package, one record: these facts belong to NDC 62032-100-36 alone.

Record
FDA NDC Directory package listing · Human prescription drug
Code segments
62032 labeler · 100 product · 36 package
Package marketed since
Jan 1, 1988
Sample package
No — commercial package
Listing certified through
Dec 31, 2026
Barcode (UPC)
0362032100364, 0362032116365, 0362032101361
FDA record last changed
Oct 1, 2026

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 62032-100-36
Product NDC 62032-100
11-digit billing NDC 62032010036
RxCUI 197795
UNII 4Y5P7MUD51, 95OOS7VE0Y, XV74C1N1AE
UPC 0362032100364, 0362032116365, 0362032101361
SPL Set ID e5c450af-958e-41e3-9c2f-fda76b3596f5
Established class (EPC) Melanin Synthesis Inhibitor
Mechanism of action Melanin Synthesis Inhibitors
Physiologic effect Depigmenting Activity
DEA schedule Non-controlled
Marketing category UNAPPROVED DRUG OTHER
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 1988-01-01
Route TOPICAL
Dosage form CREAM
Substance HYDROQUINONE

Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification

GCN Seq No 006313
GCN 24883
HICL code 002721
Ingredient (HICL) Hydroquinone
HIC1 code L
Therapeutic class — broad (HIC1) Skin/Subcutaneous Tissue
HIC2 code L9
Therapeutic class — intermediate (HIC2) Dermatologic Preparations,Miscellaneous
HIC3 code L9C
Therapeutic class — specific (HIC3) Hypopigmentation Agents
AHFS code 84:50.04.00
AHFS class Depigmenting Agents
FDB label name OBAGI NU-DERM BLENDER 4% CREAM
FDB brand name Nu-Derm
Legend status F — Federal legend — prescription drug or device
Quick answers
  • GSN (GCN sequence number): 006313
  • GCN: 24883
  • HICL (First Databank): 002721
  • AHFS class code: 84:50.04.00
  • RxCUI (RxNorm): 197795
Why two NDCs? The FDA registers this code as 62032-100-36 — a 5-3-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the product segment → 62032-0100-36. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

RxNorm drug class

This medicine belongs to the Melanin Synthesis Inhibitor class.

Pharmacologic class Melanin Synthesis Inhibitor
Drug family (ATC) Other dermatologicals
How it works Melanin Synthesis Inhibitors
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.

Clinical

Label name OBAGI NU-DERM BLENDER 4% CREAM Ingredient Hydroquinone
🧪 What is this product?

Nu-Derm Blender is a topical cream containing hydroquinone 40 mg/g, marketed as a skin lightener and blending product. Hydroquinone is a melanin synthesis inhibitor typically used to reduce the appearance of dark spots, uneven skin tone, and hyperpigmentation on the skin. This product is an unapproved drug and is not FDA-approved. The cream is applied directly to affected skin areas.

Supplement & herbal interactions

🌿 Drug–supplement interaction checker →
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer gPer package
Retail pharmacies payNADAC · weekly Not in the retail survey — common for institutional, discontinued, or low-volume packs.
Medicaid paysCMS SDUD · 12 mo No recent Medicaid claims on file for this NDC — rare and low-volume NDCs are suppressed in the public data.
Medicare drug plans payPart D · quarterly No Part D plan price is available for this NDC in our data.
ℹ️
No price is published for this exact package yet. CMS surveys NADAC per package size, so a different pack of the same drug often has one.
Try another pack size: 28 g
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Marketing startMarketing endStatus
62032-0100-10 62032-100-10 Main listing 28 g in 1 BOTTLE, PLASTIC 1988-01-01 — Active
62032-0100-36 You're viewing this 57 g in 1 BOTTLE, PLASTIC 1988-01-01 — Active

You're viewing the largest of 2 pack sizes for this product.

Pack size FAQ

What quantity is in this package?
This package contains 57 g — 57 g in 1 bottle, plastic.
How does this package differ from NDC 62032-0100-10?
Both are NU-DERM BLENDER Skin Lightener and Blending HYDROQUINONE 40 mg/g Cream — the drug itself is identical. This page's package is the 57 g one, while NDC 62032-0100-10 is the 28 g package.
What NDC number is used to bill for this package of NU-DERM BLENDER Skin Lightener and Blending HYDROQUINONE 40 mg/g Cream?
Use the 11-digit billing form listed in the identifiers section of this page. Pharmacy and medical claims use the 11-digit form; the FDA label may print a shorter form of the same code.

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Hydroquinone 4% 40 mg/g 75834-0137-01 Nivagen 1 tube $0.461 — Availability likely —
Hydroquinone 4% 40 mg/g 42192-0151-01 Acella 1 tube $0.513 — Availability likely —
Hydroquinone 40 mg/g 69367-0174-01 Westminster 1 tube $0.513 — Availability likely —
hydroquinone 40 mg/g 10135-0724-99 Marlex 1 tube — — FDA listed —
Hydroquinone cream 40 mg/g 24689-0101-01 APNAR 1 tube — — FDA listed —
Hydroquinone 4% 40 mg/g 50405-0800-01 SOHM, 1 tube — — FDA listed —
NU-DERM BLENDER Skin Lightener and Blending 40 mg/gthis 62032-0100-36 Obagi 57 g — — FDA listed —
NU-DERM CLEAR Skin Bleaching and Corrector 40 mg/g 62032-0101-36 Obagi 57 g — — FDA listed —
Obagi-C Rx system C-Therapy Night Skin Lightening with Vitamins C and E 40 mg/g 62032-0105-36 Obagi 57 g — — FDA listed —
NU-DERM SUNFADER Skin Lightener with Sunscreen (SPF 15) PABA FREE 40 mg/g; 75 mg/g; 55 mg/g 62032-0116-36 Obagi 57 g — — FDA listed —
Hydroquinone 4% 40 mg/g 71399-0400-01 Akron 28.35 g — — FDA listed —
Hydroquinone 4% 40 mg/g 72162-2422-02 Bryant 1 tube — — FDA listed —
Hydro-Q 40 mg/g 30815-0040-01 Dermavance 1 tube — — FDA listed —
About this product: other versions of the same ingredient, strength and form are listed above, least expensive first, with FDA equivalence ratings where available.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
1988
On the market since
Jan 1988
📍
2026
Currently FDA-listed
38 years listed
🔒
·
No generic listed yet
brand only
ℹ️No FDA-approved generic found

We did not find an FDA-approved generic match for this exact strength, form and route.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

What it looks like

Color White
One label can cover several strengths, so colors may be combined — always confirm a loose pill against the dispensed prescription label or a pharmacist.
Where does this data come from?
Physical description (imprint, shape, color, scoring, coating) from this product’s FDA Structured Product Labeling (SPL), mirrored from DailyMed / openFDA.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.

  • UNII 9E8X80D2L0
    A synthetic form of vitamin E used as an antioxidant and preservative in medications. It helps prevent the active ingredients from degrading when exposed to oxygen or light.
  • UNII PQ6CK8PD0R
    Ascorbic acid, also known as vitamin C, is a white crystalline powder. It serves as an antioxidant to prevent degradation of other ingredients and may also function as a preservative in the formulation.
  • UNII 1P9D0Z171K
    BHT is a synthetic antioxidant that prevents fats and oils in medicines from breaking down and becoming rancid. It helps keep the product stable and effective during storage.
  • UNII 936JST6JCN
    Cetyl alcohol is a waxy, fatty substance derived from plant or animal sources. It acts as an emulsifier and thickener in medicines, helping blend oil and water components and giving products a smooth, creamy texture.
  • UNII 7FLD91C86K
    Edetate disodium is a chemical compound that binds and removes certain metal ions. In medicines, it acts as a preservative and stabilizer by preventing metals like calcium from interfering with the product's shelf life and consistency.
  • UNII PDC6A3C0OX
    Glycerin is a clear, thick liquid derived from plant oils or fats. It acts as a humectant to retain moisture, a sweetener, and a solvent in medications.
  • UNII 33X04XA5AT
    Lactic acid is a naturally occurring organic acid derived from milk or plant sources. It lowers and maintains pH in formulations, helps preserve the product, and can enhance ingredient stability and absorption.
  • UNII A2I8C7HI9T
    Methylparaben is a preservative derived from benzoic acid that prevents growth of bacteria, fungi, and mold in medicines. It extends the product's shelf life and maintains safety during storage.
  • UNII DR0K5NOJ4R
    Phenyl trimethicone is a silicone-based lubricant and glidant. It helps powder particles flow smoothly and reduces friction during tablet or capsule manufacturing and filling.
  • UNII 88R97D8U8A
    A synthetic liquid derived from propylene glycol and myristic acid. It functions as an emollient and solvent in topical formulations, helping to soften the skin and improve the texture and spreadability of the product.
  • UNII Z8IX2SC1OH
    Propylparaben is a chemical preservative used to prevent bacterial and fungal growth in medicines and personal care products. It helps extend shelf life and maintain product safety during storage.
  • UNII 368GB5141J
    A detergent and foaming agent derived from coconut or palm oil. In medications, it helps break down and mix oil and water-based ingredients, aids in tablet disintegration, and improves how the drug dissolves and spreads in the mouth or digestive system.
  • UNII 4VON5FNS3C
    Sodium metabisulfite is a preservative derived from sulfur compounds. It prevents microbial growth and oxidation in medicines, helping extend shelf life and maintain product stability.
  • UNII H8O4040BHD
    Trolamine salicylate is a salt formed from salicylic acid and triethanolamine. It's used in topical medicines as an anti-inflammatory agent and penetration enhancer to help active ingredients absorb through the skin.
  • UNII 059QF0KO0R
    Water is a liquid solvent that dissolves and mixes ingredients together in liquid medicines, syrups, and injections. It helps distribute the active drug evenly throughout the product.

15 inactive ingredients listed in the exact product block matched to this NDC.

Where does this data come from?
Data sourced from official FDA Structured Product Labeling (SPL) via DailyMed — ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerObagi Cosmeceuticals LLC
Labeler code62032
First marketedJan 1988
Product typeHuman Prescription Drug
Portfolio47 products on file

More NDCs from Obagi Cosmeceuticals LLC labeler code 62032

The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

Full prescribing information FDA SPL

The complete FDA label for this product — the official prescribing information, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage ⏱️ Dosage and Administration ⛔ Contraindications ⚠️ Warnings 🤒 Adverse Reactions 🤰 Pregnancy 🧒 Pediatric Use 🧬 Clinical Pharmacology 📦 How Supplied / Storage and Handling 📦 Storage and Handling 📋 Description ⚠️ Precautions 🍼 Nursing Mothers 📄 Package Label / Principal Display Panel
🎯 Indications and Usage 25 words ▾

INDICATIONS AND USAGE For the gradual bleaching of hyperpigmented skin conditions such as chloasma, melasma, freckles, senile lentigines, and other unwanted areas of melanin hyperpigmentation.

⏱️ Dosage and Administration 71 words ▾

DOSAGE AND ADMINISTRATION A thin application should be applied once or twice daily or as directed by a physician. If no improvement is seen after three (3) months of treatment, use of this product should be discontinued. Sun exposure should be limited by using a sunscreen agent, a sunblocking agent, or protective clothing to cover bleached skin when using and after using this product in order to prevent darkening from reoccurring.

⛔ Contraindications 41 words ▾

CONTRAINDICATIONS People with prior history of sensitivity or allergic reaction to this product or any of its ingredients should not use it. The safety of topical hydroquinone use during pregnancy or in children (12 years and under) has not been established.

⚠️ Warnings 178 words ▾

WARNINGS Hydroquinone is a skin-bleaching agent, which may produce unwanted cosmetic effects if not used as directed. The physician should be familiar with the contents of this insert before prescribing or dispensing this product. Test for skin sensitivity before using by applying a small amount to an unbroken patch of skin and check within 24 hours.

Minor redness is not a contraindication, but where there is itching or vesicle formation or excessive inflammatory response, product should be discontinued and physician consulted. Close patient supervision is recommended. Warnings: Avoid contact with eyes, nose, mouth, and lips.In case of accidental contact, patient should rinse thoroughly with water and contact a physician.

Sunscreen use is an essential aspect of hydroquinone therapy because even minimal sunlight exposure sustains melanocytic activity. Contains sodium metabisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low.

Sulfite sensitivity is seen more frequently in asthmatic than in nonasthmatic people .

🤒 Adverse Reactions 29 words ▾

ADVERSE REACTIONS No systemic adverse reactions have been reported. Occasional hypersensitivity (localized contact dermatitis) may occur, in which case the product should be discontinued and the physician notified immediately.

🤰 Pregnancy 61 words ▾

Pregnancy Category C Animal reproduction studies have not been conducted with topical hydroquinone. It is also not known whether hydroquinone can cause fetal harm when used topically on a pregnant woman or affect reproductive capacity. It is not known to what degree, if any, topical hydroquinone is absorbed systemically. Topical hydroquinone should be used on pregnant women only when clearly indicated.

🧒 Pediatric Use 17 words ▾

Pediatric Usage Safety and effectiveness in children below the age of 12 years have not been established.

🧬 Clinical Pharmacology 73 words ▾

CLINICAL PHARMACOLOGY Topical application of hydroquinone produces a reversible depigmentation of the skin by inhibition of the enzymatic oxidation of tyrosine to 3, 4-dihydroxyphenylalanine (DOPA) and suppression of other melanocyte metabolic processes. Exposure to sunlight or ultraviolet light will cause repigmentation of the bleached areas, which may be prevented by the use of sunblocking agents or sunscreen agents contained in Obagi Nu-Derm Sunfader and Obagi Nu-Derm Sun Shield Matte Broad Spectrum SPF 50.

📦 How Supplied / Storage and Handling 71 words ▾

HOW SUPPLIED Obagi Nu-Derm Clear is available as follows: Net wt. 2 oz. (57 g) bottle NDC 62032-101-36 Obagi Nu-Derm Blender is available as follows: Net wt. 2 oz. (57 g) bottle NDC 62032-100-36 Net wt. 1 oz. (28 g) bottle NDC 62032-100-10 Obagi Nu-Derm Sunfader is available as follows: Net wt. 2 oz. (57 g) bottle NDC 62032-116-36 Store at controlled room temperature: 15°C-25°C (59°F-77°F). Keep out of direct sunlight.

📦 Storage and Handling 12 words ▾

Store at controlled room temperature: 15°C-25°C (59°F-77°F). Keep out of direct sunlight.

📋 Description 175 words ▾

DESCRIPTION Hydroquinone is 1, 4-benzenediol. The drug is freely soluble in water and in alcohol. Chemically, hydroquinone is designed as p-dihydroxybenzene; the empirical formula is C 6 H 6 O 2 ; molecular weight is 110.11 g/mol.

The chemical structure is in the diagram below. Each gram of Obagi Nu-Derm Clear contains: Active ingredient: Hydroquinone USP, 4% (40 mg/g) Inactive ingredients: water, cetyl alcohol, glycerin, sodium lauryl sulfate, stearyl alcohol, lactic acid, tocopheryl acetate, ascorbic acid, sodium metabisulfite, disodium EDTA, methylparaben, BHT, propylparaben, saponins, butylparaben Each gram of Obagi Nu-Derm Blender contains: Active ingredient: Hydroquinone USP, 4% (40 mg/g) Inactive ingredients: water, glycerin, cetyl alcohol, PPG-2 myristyl ether propionate, sodium lauryl sulfate, TEA-salicylate, lactic acid, phenyl trimethicone, tocopheryl acetate, sodium metabisulfite, ascorbic acid, methylparaben, disodium EDTA, propylparaben, saponins, BHT Each gram of Obagi Nu-Derm Sunfader contains: Active ingredients: Hydroquinone USP, 4% (40 mg/g); Octinoxate USP, 7.5%; Oxybenzone USP, 5.5% Inactive ingredients: water, cetyl alcohol, glycerin, sodium lauryl sulfate, stearyl alcohol, tocopheryl acetate, ascorbic acid, sodium metabisulfite, disodium EDTA, methylparaben, BHT, saponins, propylparaben, butylparaben Chemical Structure

⚠️ Precautions 143 words ▾

PRECAUTIONS (Also see WARNINGS ) Treatment should be limited to relatively small areas of the body at one time since some patients experience a transient skin reddening and a mild burning sensation, which does not preclude treatment. Pregnancy Category C Animal reproduction studies have not been conducted with topical hydroquinone. It is also not known whether hydroquinone can cause fetal harm when used topically on a pregnant woman or affect reproductive capacity.

It is not known to what degree, if any, topical hydroquinone is absorbed systemically. Topical hydroquinone should be used on pregnant women only when clearly indicated. Nursing Mothers It is not known whether topical hydroquinone is absorbed or excreted in human milk.

Caution is advised when topical hydroquinone is used by a nursing mother. Pediatric Usage Safety and effectiveness in children below the age of 12 years have not been established.

🍼 Nursing Mothers 28 words ▾

Nursing Mothers It is not known whether topical hydroquinone is absorbed or excreted in human milk. Caution is advised when topical hydroquinone is used by a nursing mother.

📄 Package Label / Principal Display Panel 135 words ▾

PRINCIPAL DISPLAY PANEL - 57 g Bottle Label - 3 OBAGI NU-DERM ® NDC 62032-101-36 AM CLEAR PM 3 SKIN BLEACHING & CORRECTOR CREAM HYDROQUINONE USP, 4% Rx ONLY Net wt. 2 oz. (57g) PRINCIPAL DISPLAY PANEL - 57 g Bottle Label - 3

PRINCIPAL DISPLAY PANEL - 57 g Bottle Label - 5 OBAGI NU-DERM ® NDC 62032-100-36 BLENDER ® PM 5 SKIN LIGHTENER & BLENDING CREAM HYDROQUINONE USP, 4% Rx ONLY Net wt. 2 oz. (57g) PRINCIPAL DISPLAY PANEL - 57 g Bottle Label - 5

PRINCIPAL DISPLAY PANEL - 57 g Bottle Label - 6 OBAGI NU-DERM ® NDC 62032-116-36 AM 6 SUNFADER ® HYDROQUINONE USP, 4% SKIN LIGHTENER WITH SUNSCREEN (SPF 15) PABA-FREE Rx only Net wt. 2 oz. (57 g) PRINCIPAL DISPLAY PANEL - 57 g Bottle Label - 6

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

About this NDC listing & data coverage

Finished prescription product Marketed without an FDA application

Listed without an FDA application

This product's marketing category indicates it is marketed without an approved FDA application (no NDA, ANDA, or BLA on file). Having an NDC does not by itself establish FDA approval — the NDC Directory is a listing system, not an approval decision. Approval-linked data such as Orange Book therapeutic-equivalence ratings therefore does not apply.

What data is (and isn’t) available for this NDC — tap to expand
NDC identity (package / product / labeler codes) ✓ Available
Labeler ✓ Available
Product & package description ✓ Available
Marketing category & status ✓ Available
Active ingredient / dosage form / route ✓ Available
FDA label (SPL via DailyMed) ✓ Available
Package photos ✓ Available
Inactive ingredients (structured) ✓ Available
NADAC pharmacy acquisition price (CMS) — Not published for this NDC CMS publishes NADAC only for NDCs reported in its retail-pharmacy survey.
Orange Book / therapeutic-equivalence data — Not published for this NDC Applies only to products approved under an NDA/ANDA; many listings are out of scope.
HCPCS J-code billing crosswalk — Not published for this NDC Most self-administered / retail products have no J-code — that is normal.
Medicaid utilization (CMS SDUD) — Not published for this NDC CMS reports utilization only for NDCs with Medicaid claims above its privacy threshold.
“Not published” reflects what the public FDA / CMS / NLM sources provide for this exact package code — it is a property of the data feeds, not a judgment about the product.

Questions about this listing

Is this NDC FDA-approved?
An NDC listing does not by itself establish FDA approval — the NDC Directory records that a product is listed with FDA, not that it was reviewed and approved. This listing's marketing category is "Unapproved Drug Other". Products approved under an application carry an NDA, ANDA, or BLA number.
Why is there no price listed?
The pricing shown on our NDC pages comes from CMS NADAC, a voluntary survey of retail community pharmacy invoices. CMS does not publish a NADAC for every NDC — packages outside the retail survey (institutional and hospital products, bulk packages, discontinued items, and many OTC items) may never receive one. A missing price reflects the survey's scope, not this product's actual cost, and does not mean the product is free or unavailable.
Is the NDC printed on the package the same as the 11-digit billing NDC?
Yes, they identify this exact package in different formats. The form printed on the packaging and shown on DailyMed is the one the FDA registered. Insurance claims use a fixed 11-digit 5-4-2 format, so the short segment is padded with a leading zero and the dashes are dropped. The Identity section at the top of this page lists each form of this code.
Is this package still being marketed?
Yes, per the latest FDA NDC Directory data on this page: this package is listed as actively marketed, with no marketing end date reported by Obagi Cosmeceuticals LLC. Listing status can change — the directory data on this page refreshes weekly.
Does this product come in other package sizes?
Yes — the FDA directory lists 1 other package presentation of this same product, including 28 g (62032-0100-10). Each has its own NDC and its own page — see the package list near the top of this page.
Who lists this product with the FDA?
Obagi Cosmeceuticals LLC is the labeler of record for this NDC — the company under whose FDA-assigned code the package is listed. The labeler may be the manufacturer itself or a distributor marketing the product under its own code.
Do I need a prescription for this product?
This NDC is listed with FDA as a prescription product, so it is dispensed under a prescriber's order. Your pharmacist can tell you whether any over-the-counter forms of the same medication exist.
This page identifies an FDA-listed package (the NDC) and reports public regulatory and pricing data about the listing. It is reference information, not a medical recommendation — talk to your pharmacist or prescriber about your own medication.
Where does this data come from?
Listing facts (marketing category, packager status, marketing dates) from the FDA openFDA NDC Directory; label availability from DailyMed; pricing coverage from CMS NADAC; equivalence scope from the FDA Orange Book.
← 62032-0002-07 · Obagi 62032-0101-36 · Obagi →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.